Trials / Completed
CompletedNCT00189319
To Evaluate the Impact of Oral Flecainide on Quality of Life in Patients With Paroxysmal Atrial Fibrillation
Impact of Oral Controlled Release Flecainide Acetate Capsules on Health-Related QoL in Patients With Paroxysmal Atrial Fibrillation
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (planned)
- Sponsor
- MEDA Pharma GmbH & Co. KG · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the management of paroxysmal atrial fibrillation with controlled release flecainide on patient's quality of life.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Flecainide controlled release |
Timeline
- Start date
- 2003-09-01
- First posted
- 2005-09-19
- Last updated
- 2022-02-07
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT00189319. Inclusion in this directory is not an endorsement.